Observations on the occurrence of exacerbations in clinical course of systemic lupus erythematosus

Journal of Medical Investigation

Volumn 55, Issue 1-2, 2008, Pages 112-119

  Tomioka, Reiko ^a   Tani, Kenji ^a   Sato, Keiko ^a   Suzuka, Chiyuki ^a   Toyoda, Yuko ^a   Kishi, Jun ^a   Sone, Saburo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Anti Sm antibodies; Exacerbation; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT CH50; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE; SM ANTIBODY;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE INCREASE; FEMALE; HUMAN; INCIDENCE; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PROGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT;

ADULT; AGE FACTORS; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; COMPLEMENT SYSTEM PROTEINS; DISEASE PROGRESSION; FEMALE; FORECASTING; HUMANS; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PLATELET COUNT; RIBONUCLEOPROTEINS, SMALL NUCLEAR;

EID: 43149102674     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.55.112     Document Type: Article

References (24)

1. Goldblatt F, Isenberg DA : New therapies for systemic lupus erythematosus : Clin Exp Immunol 140 : 205-212, 2005
2. Hochberg MC, Boyd RE, Ahearn JM, Arnett FC, Bias WB, Provost TT, Stevens MB : Systemic lupus erythematosus : A review of clinic-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 64 : 285-295, 1985
3. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E : Systemic lupus international collaborative clinics : Development of a damage index in systemic lupus erythematosus. J Rheumatol 19 : 1820-1821, 1992
4. Gripenberg M, Helve T : Outcome of systemic lupus erythematosus : A study of 66 patients over 7 years with special reference to the predictive value of anti-DNA determinations. Scand J Rheumatol 20 : 104-109, 1991
5. Peschken CA, Esdaile JM : Systemic lupus erythematosus in North American Indians : A population based study. J Rheumatol 27 : 1884-1891, 2000
6. Rubin LA, Urovitz MB, Gladman DD : Mortality in systemic lupus erythematosus : The bimodal pattern revisited. Q J Med 55 : 87-98, 1985
7. Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcon GS : Survival impact of autoantibodies in systemic lupus erythematosus. J Rheumatol 21 : 224-228, 1994
8. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ : The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 : 1271-1277, 1982
9. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH : Derivation of the SLEDAI : A disease activity index for lupus patients. Arthritis Rheum 35 : 630-640, 1992
10. Swaak AJG, Nossent JC, Bronsveld W, van Rooyen A, Nieuwenhuys EJ, Theuns L, Smeenk RJT : Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course : Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 48 : 455-460, 1989
11. Bujan S, Ordi-Ros J, Paredes J, Mauri M, Matas L, Cortes J, Vilardel M : Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann Rheum Dis 62 : 859-865, 2003
12. Albert DA, Hadler NM, Ropes MW : Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus. Arthritis Rheum 22 : 945-953, 1979
13. Cathcart ES, Idelson BA, Scheinberg MA, Couser WG : Beneficial effects of methlprednisolone pulse therpy in diffuse proliferative lupus nephritis. Lancet 1 : 163-166, 1976
14. Levinsky RJ, Cameron JS, Soothill JF : Serum immune complexes and disease activity in lupus nephritis. Lancet 1 : 564-567, 1977
15. Isenberg DA, Morrow WJ, Snaith ML : Methyl prednisolone pulse therapy in the treatment of systemic lupus erythematosus. Ann Rheum Dis 41 : 247-351, 1982
16. Langhoff E, Ladefoged J : Relative immunosuppressive potency of various corticosteroids measured in vitro. Eur J Clin Pharmacol 25 : 459-462, 1983
17. Massardo L, Jacobelli S, Leissner M, Gozalez M, Villarroel L, Rivero S : High-dose invravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus 1 : 401-405, 1992
18. Hoch S, Schur PH : Methylprednisolone pulse therapy for lupus nephritis : A followup study. Clin Exp Rheumatol 2 : 313-320, 1984
19. Felson DT, Anderson J : Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis : Results of a pooled analysis. N Engl J Med 311 : 1528-1533, 1984
20. Takada K, Illei GG, Boumpas DT : Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 10 : 154-161, 2001
21. Bansal VK, Beto JA : Treatment of lupus nephritis : A meta-analysis of clinical trials. Am J Kidney Dis 29 : 193-199, 1977
22. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR : Systemic lupus erythematosus. Lancet 357 : 1027-1032, 2001
23. Alarcon-Segovia D, Fishbein E, Reyes PA, Dies H, Shwadsky S : Antinuclear antibodies in patients on anticonvulsant therapy. Clin Exp Immunol 12 : 39-47, 1972
24. Sabharwal UK Fong S, Hoch S, Cook RD, Vaghan JH, Curd JG : Complement activation by antibodies to Sm in systemic lupus erythematosus. Clin Exp Immunol 51 : 317-324, 1983